Welcome to our dedicated page for Oragenics SEC filings (Ticker: OGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oragenics, Inc. (OGEN) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Oragenics is a clinical-stage biotechnology company focused on intranasal therapeutics for neurological disorders, led by its concussion and mild traumatic brain injury candidate ONP-002. Through its filings, the company discloses material agreements, financing transactions, governance changes, and details of its development strategy.
Investors can review current reports on Form 8-K to see how Oragenics documents key events such as public offerings of Series H Convertible Preferred Stock and Warrants, the entry into material agreements with its placement agent, updates on NYSE American listing compliance, settlements of disputes, and appointments and compensation of directors and executive officers. These 8-K filings also frequently incorporate press releases that summarize shareholder updates, clinical progress, and strategic partnerships.
Registration statements on Form S-1 and related amendments outline the structure and terms of Oragenics’ securities offerings, including the rights of holders of Series H preferred stock, conversion features into common stock, dividend provisions, and potential dilution. These documents also describe the company’s status as a smaller reporting company, its principal executive offices in Sarasota, Florida, and its focus on nasal delivery of pharmaceutical medications in neurology and infectious diseases.
Through this page, users can also locate exhibits referenced in filings, such as equity incentive plans, stock option award forms, at-the-market sales agreements, and key collaboration or license agreements. Together, these materials provide a detailed view of Oragenics’ capital structure, governance framework, and contractual relationships that support its ONP-002 program and intranasal platform.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, S-1 registrations, and other submissions. Real-time updates from EDGAR, combined with structured access to forms related to financings, governance, and listing compliance, allow investors to follow how Oragenics is funding and governing its clinical-stage operations over time.
Oragenics, Inc. has filed a shelf registration statement that would allow it to offer and sell up to
The company is using this flexible structure so it can complete one or more offerings, with specific terms and prices to be set in future prospectus supplements. As of January 21, 2026, Oragenics’ public float was about
Oragenics, Inc. entered into an amendment with Dawson James Securities Inc. to update its at-the-market common stock sales arrangement. The company already had an At-the-Market Sales Agreement that allows it to issue and sell shares of its common stock from time to time through Dawson James as sales agent or principal, in transactions deemed "at the market offerings" under securities regulations.
The new amendment, dated January 22, 2026, extends the term of this sales arrangement so that it will now expire at the earlier of either the sale of all shares covered by the agreement or the later of the expiration of Oragenics’ shelf registration statement on Form S-3 and any replacement registration statement filed under applicable Securities Act rules. All other terms, conditions, and covenants of the original Sales Agreement remain unchanged.
Oragenics, Inc. director Fred Telling filed an amended insider trading report covering a small stock sale and a new option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446, and held 948 shares directly after the transaction. The filing notes that the shares were sold in multiple trades between $0.9440 and $0.9451.
The amendment also reports a grant of 125,000 non-employee director stock options on 12/11/2025 with an exercise price of $0.93 per share, vesting immediately and expiring on 12/11/2035. The company previously completed a 1-for-30 reverse stock split of its common stock, and this amendment corrects the amount of securities beneficially owned to reflect that corporate action.
Oragenics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 412,654 shares of Oragenics common stock. This position represents 9.9% of the outstanding common shares as of the filing. The reporting persons state they have shared voting and dispositive power over all 412,654 shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Oragenics, but instead are held on a passive basis consistent with a Schedule 13G filing.
Oragenics, Inc. filed a current report to share that it will use an updated investor presentation, dated January 20, 2026, in a presentation by its CEO at the Sequire Investor Summit. The same presentation, furnished as Exhibit 99.1, will also be available on the company’s website under the “Presentations” tab in the “News and Media” section. The company notes that this information is being furnished under Regulation FD and is not deemed “filed” for liability purposes under the Exchange Act unless specifically stated otherwise.
Oragenics, Inc. reported an equity award to its CEO and CFO, Janet Huffman. On 12/11/2025 she was granted an employee stock option to buy 250,000 shares of Oragenics common stock at an exercise price of $0.93 per share under the Company's 2021 Equity Incentive Plan, as amended.
One third of the options vest on the first anniversary of the grant date, with the remaining two thirds vesting in equal annual installments on the second and third anniversaries, provided she continues to perform services for the company through each vesting date. The options are scheduled to expire on 12/11/2035, and the exercise price was set at the closing price of the common stock on the grant date.
Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.
Oragenics Inc. director Fred Telling reported a small sale of company stock and a new stock option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446 per share, leaving him with 34,538 shares of Oragenics common stock held directly.
On 12/11/2025, he received a non-employee director option award for 125,000 shares of Oragenics common stock under the company’s 2021 Equity Incentive Plan. The options have an exercise price of $0.93 per share, vest immediately on the grant date, and are scheduled to expire on 12/11/2035.
Oragenics Inc (OGEN) reported a grant of non-employee director stock options to director John Gandolfo. On 12/11/2025 he received options to purchase 125,000 shares of common stock at an exercise price of $ 0.93, with an expiration date of 12/11/2035.
The award was made under Oragenics' 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The options vest immediately, and Gandolfo beneficially holds 125,000 derivative securities directly following this transaction.
Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.
The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
